Can-Fite to Present at The LD Micro 500 Virtual Conference on September 1, 2020
Can-Fite BioPharma (NYSE American: CANF) announced its participation in the 12th annual LD 500 Virtual Conference, scheduled for September 1, 2020. CEO Dr. Pnina Fishman will present at 9:20 AM EST and conduct private meetings with investors. The event aims to attract around 20,000 attendees and features 300 companies. Can-Fite plans to update on its advanced pipeline, including Phase III trials for rheumatoid arthritis, psoriasis, and liver cancer, alongside new studies for COVID-19 and NAFLD/NASH. Investors can register to view the presentation online.
- None.
- None.
LOS ANGELES, CA / ACCESSWIRE / August 26, 2020 / Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it will be presenting at the 12th annual LD 500 on Tuesday, September 1, 2020 at 9:20 AM EST / 6:20 AM PST. The LD 500 will take place on September 1st through the 4th. Investors interested in viewing the presentation may register here: https://ld-micro-conference.events.issuerdirect.com/
Can-Fite CEO Dr. Pnina Fishman will present to a live public audience, and management will conduct private 1x1 meetings with registered investors. LD Micro expects 20,000 attendees and 300 featured companies. Can-Fite plans to update investors on its advanced clinical pipeline including two ongoing Phase III trials in rheumatoid arthritis and psoriasis, an upcoming pivotal Phase III study in liver cancer, and two upcoming clinical trials in the treatment of COVID-19 and NAFLD/NASH.
Chris Lahiji, Founder of LD stated, "We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space."
Can-Fite's profile for the conference may be viewed here: http://www.ldmicro.com/profile/CANF
Profiles powered by LD Micro - News Compliments of ACCESSWIRE
About LD Micro
Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone. For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and COVID-19. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the impact of the recent outbreak of coronavirus; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.
Contact
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
SOURCE: Can-Fite BioPharma via LD Micro
View source version on accesswire.com:
https://www.accesswire.com/602792/Can-Fite-to-Present-at-The-LD-Micro-500-Virtual-Conference-on-September-1-2020
FAQ
When is Can-Fite presenting at the LD Micro 500?
What is the focus of Can-Fite's presentation at the LD 500?
How can investors view Can-Fite's presentation at the LD Micro 500?
What trials is Can-Fite currently conducting?
How many companies are participating in the LD Micro 500?
